JP2017529074A5 - - Google Patents

Download PDF

Info

Publication number
JP2017529074A5
JP2017529074A5 JP2017513004A JP2017513004A JP2017529074A5 JP 2017529074 A5 JP2017529074 A5 JP 2017529074A5 JP 2017513004 A JP2017513004 A JP 2017513004A JP 2017513004 A JP2017513004 A JP 2017513004A JP 2017529074 A5 JP2017529074 A5 JP 2017529074A5
Authority
JP
Japan
Prior art keywords
mrna
cancer
ercc1 isoform
therapeutic agent
isoform
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017513004A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017529074A (ja
JP7057668B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2015/071170 external-priority patent/WO2016042009A1/en
Publication of JP2017529074A publication Critical patent/JP2017529074A/ja
Publication of JP2017529074A5 publication Critical patent/JP2017529074A5/ja
Application granted granted Critical
Publication of JP7057668B2 publication Critical patent/JP7057668B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017513004A 2014-09-18 2015-09-16 治療剤に対する抵抗性の診断に使用するためのＥＲＣＣ１アイソフォーム３のｍＲＮＡおよび／またはタンパク質ならびにこのｍＲＮＡおよび／またはタンパク質を使用する治療剤に対する抵抗性を診断するための方法 Active JP7057668B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14185247 2014-09-18
EP14185247.5 2014-09-18
PCT/EP2015/071170 WO2016042009A1 (en) 2014-09-18 2015-09-16 Mrna and/or protein of ercc1 isoform 3 for use in diagnosing a resistance against a therapeutic agent and method for diagnosing a resistance against a therapeutic agent using said mrna and/or protein

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020168483A Division JP2021019612A (ja) 2014-09-18 2020-10-05 治療剤に対する抵抗性の診断に使用するためのＥＲＣＣ１アイソフォーム３のｍＲＮＡおよび／またはタンパク質ならびにこのｍＲＮＡおよび／またはタンパク質を使用する治療剤に対する抵抗性を診断するための方法

Publications (3)

Publication Number Publication Date
JP2017529074A JP2017529074A (ja) 2017-10-05
JP2017529074A5 true JP2017529074A5 (https=) 2018-08-23
JP7057668B2 JP7057668B2 (ja) 2022-04-20

Family

ID=51542262

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2017513004A Active JP7057668B2 (ja) 2014-09-18 2015-09-16 治療剤に対する抵抗性の診断に使用するためのＥＲＣＣ１アイソフォーム３のｍＲＮＡおよび／またはタンパク質ならびにこのｍＲＮＡおよび／またはタンパク質を使用する治療剤に対する抵抗性を診断するための方法
JP2020168483A Pending JP2021019612A (ja) 2014-09-18 2020-10-05 治療剤に対する抵抗性の診断に使用するためのＥＲＣＣ１アイソフォーム３のｍＲＮＡおよび／またはタンパク質ならびにこのｍＲＮＡおよび／またはタンパク質を使用する治療剤に対する抵抗性を診断するための方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2020168483A Pending JP2021019612A (ja) 2014-09-18 2020-10-05 治療剤に対する抵抗性の診断に使用するためのＥＲＣＣ１アイソフォーム３のｍＲＮＡおよび／またはタンパク質ならびにこのｍＲＮＡおよび／またはタンパク質を使用する治療剤に対する抵抗性を診断するための方法

Country Status (4)

Country Link
US (1) US20170233826A1 (https=)
EP (1) EP3194616B1 (https=)
JP (2) JP7057668B2 (https=)
WO (1) WO2016042009A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20200377955A1 (en) * 2017-06-20 2020-12-03 Liquid Genomics, Inc. USE OF CELL-FREE CIRCULATING RNA (cfRNA) EXPRESSION OF PD-L1 AND ERCC1 IN PLASMA TO MONITOR RESPONSE TO THERAPY IN NSCLC
KR102780643B1 (ko) * 2020-11-04 2025-03-17 한국과학기술원 비기능성 전사체를 이용한 parp 저해제 또는 dna 손상 약물 감수성 판정방법

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE309393T1 (de) * 2001-09-06 2005-11-15 Adnagen Ag Verfahren zum qualitativen und/oder quantitativen nachweis von zellen
US9702875B2 (en) * 2006-03-14 2017-07-11 Institute Gustave-Roussy Expression of isoform 202 of ERCC1 for predicting response to cancer chemotherapy
EP2008102A4 (en) * 2006-04-18 2009-07-08 Wellstat Biologics Corp DETECTION OF PROTEINS IN NEOPLASTIC CELLS IN CIRCULATION
EP2233589A1 (en) * 2009-03-19 2010-09-29 Institut Gustave Roussy MSH2 and adjuvant cisplatin-based chemotherapy in non-small-cell lung cancer
JP2013504064A (ja) * 2009-09-03 2013-02-04 ザ スクリプス リサーチ インスティチュート 循環腫瘍細胞を分類する方法
TWI577389B (zh) * 2010-10-14 2017-04-11 維里德克斯有限責任公司 使用多專一性捕捉及雞尾酒檢測試劑檢測胰臟病患之循環腫瘤細胞的方法及套組

Similar Documents

Publication Publication Date Title
Zhao et al. Extracellular vesicles as cancer liquid biopsies: from discovery, validation, to clinical application
Kang et al. Dual‐isolation and profiling of circulating tumor cells and cancer exosomes from blood samples with melanoma using immunoaffinity‐based microfluidic interfaces
Yang et al. Elevated CD163+/CD68+ ratio at tumor invasive front is closely associated with aggressive phenotype and poor prognosis in colorectal cancer
Ahlin et al. High expression of cyclin D1 is associated to high proliferation rate and increased risk of mortality in women with ER-positive but not in ER-negative breast cancers
M Braden et al. Breast cancer biomarkers: risk assessment, diagnosis, prognosis, prediction of treatment efficacy and toxicity, and recurrence
Anantharaman et al. Programmed death-ligand 1 (PD-L1) characterization of circulating tumor cells (CTCs) in muscle invasive and metastatic bladder cancer patients
Chundong et al. Molecular diagnosis of MACC1 status in lung adenocarcinoma by immunohistochemical analysis
Munzone et al. Prognostic value of circulating tumor cells according to immunohistochemically defined molecular subtypes in advanced breast cancer
Li et al. Noninvasive Diagnosis and Molecular Phenotyping of Breast Cancer through Microbead‐Assisted Flow Cytometry Detection of Tumor‐Derived Extracellular Vesicles
EP3488238B1 (en) Combination test for colorectal cancer
Taliano et al. Calretinin expression in high-grade invasive ductal carcinoma of the breast is associated with basal-like subtype and unfavorable prognosis
AU2013263337A1 (en) Tumor cell isolation/purification process and methods for use thereof
Rim et al. Quantitative analysis of exosomes from murine lung cancer cells by flow cytometry
Minamoto et al. Loss of beclin 1 expression in ovarian cancer: A potential biomarker for predicting unfavorable outcomes
Pontikakis et al. Predictive value of ATP7b, BRCA1, BRCA2, PARP1, UIMC1 (RAP80), HOXA9, DAXX, TXN (TRX1), THBS1 (TSP1) and PRR13 (TXR1) genes in patients with epithelial ovarian cancer who received platinum-taxane first-line therapy
Shi et al. NEDD9 overexpression correlates with the progression and prognosis in gastric carcinoma
Nel et al. Formation and repair kinetics of Pt-(GpG) DNA adducts in extracted circulating tumour cells and response to platinum treatment
Xu et al. Significance and prognostic role of human epidermal growth factor receptor 2 and RAB1A expression in gastric cancer
Gheni et al. Quantitative real-time PCR assay with immunohistochemical evaluation of HER2/neu oncogene in breast cancer patients and its correlation with clinicopathological findings
Franceschini et al. Mesothelin in serum and pleural effusion in the diagnosis of malignant pleural mesothelioma with non-positive cytology
Jiang et al. Correlation between microtubule-associated gene expression and chemosensitivity of patients with stage II non-small cell lung cancer
Jagdis et al. Assessment of ERCC1 and XPF protein expression using quantitative immunohistochemistry in nasopharyngeal carcinoma patients undergoing curative intent treatment
JP2017529074A5 (https=)
Meng et al. Expression of human epidermal growth factor receptor-2 in resected rectal cancer
JP2021019612A (ja) 治療剤に対する抵抗性の診断に使用するためのＥＲＣＣ１アイソフォーム３のｍＲＮＡおよび／またはタンパク質ならびにこのｍＲＮＡおよび／またはタンパク質を使用する治療剤に対する抵抗性を診断するための方法